Provider Briefing: Papaverine Supply in 2026

Papaverine Hydrochloride injection (30 mg/mL) remains a clinically important medication across multiple specialties — from neurosurgery and vascular surgery to urology. However, its supply chain has long been fragile, and providers should be prepared for intermittent access challenges in 2026.

This briefing covers the current supply landscape, prescribing implications, alternative therapeutic options, and practical tools to support patient access.

Shortage Timeline and History

Papaverine injection has experienced documented supply disruptions:

• 2017: ASHP listed Papaverine injection as in shortage. American Regent, one of the primary manufacturers of the 30 mg/mL, 2 mL vial formulation (NDC 00517-4002-25), experienced supply constraints. No specific reason was provided.
• 2018-2024: Intermittent spot shortages at the wholesaler level, particularly affecting compounding pharmacies that rely on bulk Papaverine for Trimix and Bimix preparations.
• 2025-2026: No formal FDA shortage listing as of early 2026. Supply is generally available through major wholesalers, but individual pharmacy and regional disruptions continue to be reported.

The pattern is consistent with the broader trend affecting sterile injectable generics: concentrated manufacturing, low margins, and minimal buffer inventory create a supply chain vulnerable to even minor disruptions.

Prescribing Implications

Providers should consider the following when prescribing Papaverine:

FDA-Approved vs. Off-Label Use

Papaverine's FDA-approved indications include relief of cerebral and peripheral ischemia associated with arterial spasm, and visceral smooth muscle spasm. Notably, the 1979 FDA Advisory Committee concluded there was insufficient data to support the marketed oral indications and recommended withdrawal — though the drug remains available.

The most common contemporary use — intracavernosal injection for erectile dysfunction — is off-label. This is an important consideration for informed consent documentation, insurance appeals, and prior authorization requests.

Formulary and Coverage Considerations

• When administered in inpatient or surgical settings, Papaverine is typically covered under the facility's medical benefit.
• Outpatient use for erectile dysfunction faces significant coverage barriers. Many commercial and Medicare plans exclude ED treatments, and prior authorization requirements are common.
• Compounded formulations (Trimix, Bimix) are generally not covered by insurance, leaving patients to pay cash — typically $75-$200 per vial depending on formulation and pharmacy.

Patient Counseling Points

• Papaverine is not a controlled substance despite its opium alkaloid origin
• Intracavernosal injection technique requires proper training — consider in-office demonstration for new patients
• Priapism risk must be clearly communicated (erections lasting >4 hours require emergency medical attention)
• Hepatotoxicity monitoring: periodic liver function tests recommended for patients on prolonged therapy

Current Availability Picture

As of early 2026, Papaverine injection is available from the following supply channels:

• Wholesalers: Major distributors (McKesson, Cardinal Health, AmerisourceBergen) generally show stock, though allocation limits may apply
• Compounding pharmacies: Most compounding pharmacies that prepare Trimix/Bimix maintain dedicated Papaverine supply relationships, but bulk availability can fluctuate
• Hospital pharmacies: Institutional supply is generally adequate for surgical use

The primary challenge is at the retail pharmacy level, where Papaverine is often not a standard inventory item. Patients presenting prescriptions at chain pharmacies frequently encounter "not in stock" responses.

Cost and Access for Patients

Cost transparency helps providers anticipate and address patient concerns:

• Cash price (single 2 mL vial, 30 mg/mL): ~$65 retail; $16-$25 with discount cards
• Compounded Trimix: $75-$200 per vial (not insurance-covered)
• No manufacturer savings programs exist for Papaverine (generic medication)
• Patient assistance: NeedyMeds and RxAssist list general programs that may help qualifying patients

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a provider-facing tool that allows clinical teams to check real-time pharmacy availability for Papaverine and other medications. This can be integrated into your workflow when patients report difficulty filling prescriptions — giving your team visibility into which pharmacies currently have stock.

ASHP Drug Shortages Database

Monitor the ASHP Drug Shortages Resource Center for formal shortage listings and manufacturer updates on Papaverine injection.

Compounding Pharmacy Referral Networks

For urology practices prescribing intracavernosal therapy, maintaining relationships with 2-3 reliable compounding pharmacies ensures continuity when one source experiences supply issues. National compounding pharmacies offering mail-order service can expand patient access beyond local options.

Alternative Therapeutic Options

When Papaverine is unavailable or impractical, consider these alternatives by indication:

Erectile Dysfunction

• Alprostadil (Caverject, Edex): FDA-approved intracavernosal agent. Available as single-use injection kits. Higher per-dose cost ($40-$80) but more reliable supply.
• MUSE (Alprostadil urethral suppository): Non-injection option for patients who prefer needle-free administration.
• PDE5 inhibitors (Sildenafil, Tadalafil): First-line oral therapy per AUA guidelines. Generic Sildenafil available for under $1/pill with discount cards.

Cerebral Vasospasm

• Nimodipine (Nymalize): Standard of care for reducing neurological deficits from vasospasm after subarachnoid hemorrhage. Oral dosing preferred in most protocols.
• Nicardipine (IV): Alternative for acute intra-arterial management during neurovascular procedures.

Surgical Vascular Spasm

• Verapamil (intra-arterial): Established alternative for catheter-induced spasm and arterial graft spasm prevention.
• Nicardipine: Used in cardiovascular and interventional radiology settings.

For a patient-facing version of this information, see our article on alternatives to Papaverine.

Looking Ahead

The structural factors driving Papaverine supply vulnerability — few manufacturers, low margins, complex injectable production — are unlikely to resolve quickly. Providers can best serve their patients by:

1. Proactively discussing supply risks and alternative plans with patients starting Papaverine
2. Maintaining relationships with multiple pharmacy sources (including compounders)
3. Using tools like Medfinder to monitor real-time availability
4. Documenting off-label rationale for insurance appeals when coverage is denied

Final Thoughts

Papaverine remains a valuable therapeutic agent, particularly for intracavernosal ED therapy and surgical vasospasm management. While supply in 2026 is generally adequate, the narrow manufacturing base demands vigilance. Building flexible prescribing strategies and leveraging availability tools can ensure your patients maintain access to the treatment they need.

For a practical guide on helping patients find Papaverine, see: How to help your patients find Papaverine in stock.